China bans BioKangtai hepatitis B vaccine

26 December 2013

Chinese authorities on Friday issued a circular to ban the use of the recombinant hepatitis B vaccine produced by the Shenzhen-based BioKangtai company, reported the state news agency Xinhua.

The circular, jointly issued by the China Food and Drug Administration (CFDA) and the National Health and Family Planning Commission (NHFPC), said that four cases of infants' deaths were reported in Hunan, Guangdong and Sichuan provinces after inoculation using the vaccine.

The CFDA and the NHFPC will carry out further investigation into the cases and inspection over the company, the circular said.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >